Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatment of prostate cancer in the US.
The company said it wants to enable availability across a wide range of US locations following the recent US Food and Drug Administration approval of Gozellix and in preparation for its commercial launch during the first half of 2025.
Cardinal Health will operate as a strategic radiopharmacy distributor for Gozellix alongside Telix's in-house radiopharmacy network, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。